Inhibikase Therapeutics GAAP EPS of -$0.11
Source: SeekingAlpha
2025-08-15 06:38:19 ET
More on Inhibikase Therapeutics
- Seeking Alpha’s Quant Rating on Inhibikase Therapeutics
- Historical earnings data for Inhibikase Therapeutics
- Financial information for Inhibikase Therapeutics
Read the full article on Seeking Alpha
For further details see:
Inhibikase Therapeutics GAAP EPS of -$0.11
Inhibikase Therapeutics Inc.
NASDAQ: IKT
IKT Trading
-2.36% G/L:
$1.655 Last:
251,222 Volume:
$1.68 Open:
IKT Latest News
May 12, 2026 04:01:00 pm
Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity
April 07, 2026 08:00:00 am
Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
August 14, 2025 04:50:16 pm
Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity
IKT Stock Data
$312,546,783
59,068,475
3.59%
48
N/A
Biotechnology & Life Sciences
Healthcare
US
Wilmington
